Description
(AWP Alliance News) - RELX reported 6% underlying revenue growth at its Scientific, Technical & Medical business in the first half of 2026, with underlying adjusted operating profit up 8%, in an investor presentation. The business accounted for 28% of group revenue and 30% of adjusted operating profit.
Elsevier article submissions rose more than 20%, while published articles increased 7%. Strategic priorities include expanding research publishing volumes and accelerating decision-support product innovation, with the objective of keeping profit growth ahead of revenue growth.
https://docs.publicnow.com/FB5F447696B83F2D003CB7204832D3A09ADC662B
Disclaimer: This news brief was created using generative artificial intelligence. Relx plc published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.